Recent studies like CANTOS have raised the idea that colchicine could decrease plaque inflammation. Colchicine is an old, inexpensive anti-inflammatory medication.

Basically, there are several studies now looking this. One study has shown a decrease in plaque volume by LAPV (Low Attenuation Plaque Volume) studies. It's been termed as "intriguing" by experts such as Paul Ridker, MD at Harvard, that has focused on cv inflammation for years. Ridker was the Principle Investigator of the CANTOS trial that was announced in June 2017. The CANTOS trial created excitement and surprise in the global cardiology community, despite the fact that this has been known for over a decade.